An Update on Mpox: Focussing on Current and Emerging Antiviral Strategies
Reviews in Medical Virology · 2026-03 · 36 (2)
DOI: 10.1002/rmv.70116 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Medical Virology, online erschienen am 16.02.2026. Verfasst von Yizhuo Hou und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: Antiviral Agents, Mpox, Monkeypox. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovation Program of Shanghai Municipal Education Commission.
Abstract (Originalsprache)
The 2022 global mpox outbreak and subsequent viral evolution have exposed critical limitations in current therapeutic strategies, which predominantly rely on repurposed smallpox drugs targeting a narrow range of viral proteins. This review provides a timely and comprehensive evaluation of the mpox antiviral landscape, spanning from established clinical agents to cutting‐edge preclinical candidates. We critically analyse the ‘clinical translation gap’ observed in recent clinical trials (e.g., STOMP and PALM007), attributing the limited efficacy in mild cases to host immunopathological responses versus primary viral replication. Highlighting a strategic paradigm shift, we also discuss the 2025 breakthrough in covalent inhibitors targeting the conserved CorePro. Furthermore, we explore the integration of AI‐assisted drug design and host‐targeted therapies (HTTs) to elevate resistance barriers. By synthesising these emerging targets and multidimensional strategies, this review serves as a strategic roadmap for developing next‐generation anti‐mpox therapeutics with optimised efficacy and broader resistance profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
- Clinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai, China.
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
ORCID-Profile: Jixi Li
Förderung
- National Natural Science Foundation of China
- Innovation Program of Shanghai Municipal Education Commission
Zitieren
APA
Hou, Y., Su, Y., Li, J., & Ding, J. (2026). An Update on Mpox: Focussing on Current and Emerging Antiviral Strategies. Reviews in Medical Virology, 36(2). https://doi.org/10.1002/rmv.70116
Vancouver
Hou Y, Su Y, Li J, Ding J. An Update on Mpox: Focussing on Current and Emerging Antiviral Strategies. Reviews in Medical Virology. 2026;36(2). doi:10.1002/rmv.70116
BibTeX
@article{Hou2026,
author = {Hou, Yizhuo and Su, Yu and Li, Jixi and Ding, Jin},
title = {An Update on Mpox: Focussing on Current and Emerging Antiviral Strategies},
journal = {Reviews in Medical Virology},
year = {2026},
volume = {36},
number = {2},
doi = {10.1002/rmv.70116}
}
EUVIMED